Gilead to Discount Oral Hepatitis C Drug for Select Health Plans

In light of criticism for the high price tag of its oral hepatitis C drug Sovaldi, Gilead has made discount agreements with a number of health insurers, according to a Medscape report.

Advertisement

The drug has a list-price of $1,000 a pill, a total of $84,000 for a 12-week course of therapy. Gilead already provides a 23 percent mandated discount to government insurers.

Gilead representatives believe the concern over the drug is due to the volume of demand.

More Articles on Gastroenterology:
12 Gastroenterologist Moves & Honors
7 Gastroenterologists on Benchmarking & Colonoscopy Quality (Part 2)
AGA Supports ICD-10 Delay, Opposes Temporary SGR Fix

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.